Results 51 to 60 of about 149 (93)

Defective HLA class I antigen processing machinery in cancer. [PDF]

Cancer Immunol Immunother, 2018
Cai L, Michelakos T, Yamada T, Fan S, Wang X, Schwab JH, Ferrone CR, Ferrone S.   +7 more
europepmc   +1 more source

PONTOS DE CARBONO DA BIOMASSA DE COCO BABAÇU (ORBIGNYA SPECIOSA): OTIMIZAÇÃO DA ROTA SINTÉTICA E SUAS CARACTERIZAÇÕES [PDF]

Seminário de Iniciação Científica e Tecnológica Universidade Federal de Santa Catarina Departamento de QuímicaA cada ano, as estatísticas do câncer agravam ainda mais, tornando-se um dos principais desafios da saúde pública global. A elevada incidência,
Silva, Arthur Boesing da
core  

[Diagnostic protocol and empirical treatment in emergency department of respiratory infections]. [PDF]

Medicine (Baltimore), 2018
Graziani Noriega D, Ampuero López A.
europepmc   +1 more source

The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. [PDF]

Cancer Immunol Immunother, 2018
Anichini A, Tassi E, Grazia G, Mortarini R.   +3 more
europepmc   +1 more source

[Prevalence and risk factors for methicillin-resistant Staphylococcus aureus infection in children]. [PDF]

Rev Esp Quimioter
Marín Oliván P, Ferrando Monleón S, Bretón-Martínez JR, Piolatti Luna A, Hernández Monleón I, Fuertes Latasa C, Navarro Ortega D, Colomina Rodríguez J.   +7 more
europepmc   +1 more source

Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. [PDF]

Cancer Immunol Immunother, 2015
Trajanoski Z, Maccalli C, Mennonna D, Casorati G, Parmiani G, Dellabona P.   +5 more
europepmc   +1 more source

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? [PDF]

Cancer Immunol Immunother, 2015
Calabrò L, Ceresoli GL, di Pietro A, Cutaia O, Morra A, Ibrahim R, Maio M.   +6 more
europepmc   +1 more source

Cholesterol metabolites and tumor microenvironment: the road towards clinical translation. [PDF]

Cancer Immunol Immunother, 2016
Raccosta L, Fontana R, Corna G, Maggioni D, Moresco M, Russo V.   +5 more
europepmc   +1 more source

T cell responses to tumor: how dominant assumptions on immune activity led to a neglect of pathological functions, and how evolutionary considerations can help identify testable hypotheses for improving immunotherapy. [PDF]

Cancer Immunol Immunother, 2018
Kallikourdis M.
europepmc   +1 more source

Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. [PDF]

Cancer Immunol Immunother, 2015
Castelli C, Rivoltini L, Rodolfo M, Tazzari M, Belgiovine C, Allavena P.   +5 more
europepmc   +1 more source